Rep. Lisa C. McClain Buys Johnson & Johnson (NYSE:JNJ) Stock

Key Points

• Representative Lisa C. McClain (R-Michigan) purchased shares of Johnson & Johnson (NYSE:JNJ) valued between $1,001 and $15,000 on August 4th, as disclosed in a recent filing.
• Johnson & Johnson recently reported $2.77 earnings per share (EPS) for the quarter, exceeding analysts' expectations, with a revenue of $23.74 billion.
• The company declared a quarterly dividend of $1.30 per share, leading to an annualized dividend total of $5.20 and a yield of 2.9%.

Representative Lisa C. McClain (R-Michigan) recently bought shares of Johnson & Johnson NYSE: JNJ. In a filing disclosed on September 12th, the Representative disclosed that they had bought between $1,001 and $15,000 in Johnson & Johnson stock on August 4th. The trade occurred in the Representative's "CHARLES SCHWAB BROKERAGE ACCOUNT 924" account.

Representative Lisa C. McClain also recently made the following trade(s):

• Sold $50,001 - $100,000 in shares of Taiwan Semiconductor Manufacturing NYSE: TSM on 8/28/2025.
• Purchased $1,001 - $15,000 in shares of ACI Worldwide NASDAQ: ACIW on 8/19/2025.
• Purchased $1,001 - $15,000 in shares of HCA Healthcare NYSE: HCA on 8/19/2025.
• Sold $1,001 - $15,000 in shares of Amedisys NASDAQ: AMED on 8/18/2025.
• Purchased $1,001 - $15,000 in shares of Kite Realty Group Trust NYSE: KRG on 8/13/2025.
• Sold $1,001 - $15,000 in shares of ServiceNow NYSE: NOW on 8/13/2025.
• Purchased $1,001 - $15,000 in shares of JD.com NASDAQ: JD on 8/13/2025.
• Sold $1,001 - $15,000 in shares of Trade Desk NASDAQ: TTD on 8/13/2025.
• Sold $1,001 - $15,000 in shares of US Foods NYSE: USFD on 8/13/2025.
• Purchased $1,001 - $15,000 in shares of Agree Realty NYSE: ADC on 8/13/2025.

Johnson & Johnson Price Performance

Shares of NYSE:JNJ traded up $1.81 on Friday, reaching $175.97. 25,617,065 shares of the company were exchanged, compared to its average volume of 6,995,150. The company has a current ratio of 1.01, a quick ratio of 0.76 and a debt-to-equity ratio of 0.50. Johnson & Johnson has a 1-year low of $140.68 and a 1-year high of $181.16. The firm has a market cap of $423.80 billion, a price-to-earnings ratio of 18.82, a price-to-earnings-growth ratio of 2.22 and a beta of 0.40. The company has a 50-day moving average of $172.80 and a 200-day moving average of $161.69.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its quarterly earnings results on Wednesday, July 16th. The company reported $2.77 earnings per share for the quarter, topping analysts' consensus estimates of $2.68 by $0.09. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. The business had revenue of $23.74 billion for the quarter, compared to analysts' expectations of $22.85 billion. During the same period in the prior year, the company posted $2.82 EPS. The business's revenue for the quarter was up 5.8% on a year-over-year basis. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. Equities analysts forecast that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Tuesday, September 9th. Stockholders of record on Tuesday, August 26th were paid a dividend of $1.30 per share. The ex-dividend date of this dividend was Tuesday, August 26th. This represents a $5.20 dividend on an annualized basis and a dividend yield of 3.0%. Johnson & Johnson's dividend payout ratio is 55.61%.

Analyst Upgrades and Downgrades

JNJ has been the topic of a number of recent analyst reports. Barclays upped their price target on shares of Johnson & Johnson from $165.00 to $176.00 and gave the stock an "equal weight" rating in a research note on Thursday, July 17th. JPMorgan Chase & Co. boosted their price objective on shares of Johnson & Johnson from $185.00 to $200.00 and gave the stock a "neutral" rating in a research report on Tuesday. Royal Bank Of Canada boosted their price objective on shares of Johnson & Johnson from $181.00 to $185.00 and gave the stock an "outperform" rating in a research report on Thursday, July 17th. Wall Street Zen upgraded shares of Johnson & Johnson from a "hold" rating to a "buy" rating in a research report on Saturday, September 13th. Finally, Guggenheim reiterated a "neutral" rating and issued a $167.00 price objective (up from $164.00) on shares of Johnson & Johnson in a research report on Thursday, July 17th. Two investment analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and ten have assigned a Hold rating to the company. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $177.87.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the stock. Canal Capital Management LLC lifted its holdings in shares of Johnson & Johnson by 3.7% during the 2nd quarter. Canal Capital Management LLC now owns 49,733 shares of the company's stock worth $7,597,000 after acquiring an additional 1,783 shares during the period. Milestones Private Investment Advisors LLC purchased a new position in shares of Johnson & Johnson during the 2nd quarter worth about $318,000. NWF Advisory Services Inc. lifted its holdings in shares of Johnson & Johnson by 69.6% during the 2nd quarter. NWF Advisory Services Inc. now owns 9,850 shares of the company's stock worth $1,505,000 after acquiring an additional 4,041 shares during the period. Prospera Capital Management LLC lifted its holdings in shares of Johnson & Johnson by 12.5% during the 2nd quarter. Prospera Capital Management LLC now owns 1,868 shares of the company's stock worth $285,000 after acquiring an additional 208 shares during the period. Finally, SevenBridge Financial Group LLC lifted its holdings in shares of Johnson & Johnson by 4.3% during the 2nd quarter. SevenBridge Financial Group LLC now owns 45,124 shares of the company's stock worth $6,893,000 after acquiring an additional 1,880 shares during the period. 69.55% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Johnson & Johnson

In related news, EVP Jennifer L. Taubert sold 56,471 shares of the stock in a transaction that occurred on Thursday, September 4th. The shares were sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the completion of the sale, the executive vice president owned 178,013 shares of the company's stock, valued at approximately $31,652,491.53. This represents a 24.08% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.16% of the stock is currently owned by insiders.

About Representative McClain

Lisa McClain (Republican Party) is a member of the U.S. House, representing Michigan's 9th Congressional District. She assumed office on January 3, 2023. Her current term ends on January 3, 2027. McClain (Republican Party) is running for re-election to the U.S. House to represent Michigan's 9th Congressional District. She declared candidacy for the 2026 election. Lisa McClain lives in Romeo, Michigan. McClain earned a bachelor's degree in business administration from Northwood University. Her career experience includes founding and working as the president of North End Support Team.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.